Bausch + Lomb's $790.6M Investment Paves the Way for a New Era in Global Eye Health

Bausch + Lomb, a global leader in eye health, is thrilled to announce a monumental funding round of $790,600,000. This extraordinary investment is poised to bolster the company’s mission of protecting and enhancing the gift of sight for millions of individuals across every stage of life. With a heritage dating back to 1853, Bausch + Lomb has long been at the forefront of eye care innovation, delivering a diverse portfolio that includes more than 400 products such as contact lenses, lens care solutions, ophthalmic pharmaceuticals, surgical devices, and over-the-counter eye care products. This latest infusion of capital not only solidifies our reputation as a trailblazer in the field, but also provides critical resources to accelerate research and development initiatives, expand our manufacturing capabilities, and enhance our global commercial footprint. The funds will be strategically allocated to fortify our cutting-edge research labs and drive the development of next-generation technologies designed to address the evolving needs of patients worldwide. With over 12,000 dedicated employees and a presence in nearly 100 countries, Bausch + Lomb remains committed to investing in innovations that ensure safer, more accessible, and effective eye care solutions. This capital infusion arrives at a pivotal moment, as the world increasingly recognizes the value of vision health and the need for advanced, patient-centric approaches in eye care. It is an exciting time for the company as we continue to honor our longstanding legacy while harnessing new opportunities that will shape the future of eye health globally. We look forward to delivering transformational advancements that empower people to experience life with clearer vision, reinforcing our promise to safeguard sight for generations to come.